Control ADCs for R&D
Once an antibody is en route as a candidate for antibody-drug conjugate (ADC) development, it is crucial to select suitable payload-linker complexes for ADC formulation and in the meantime, to develop assays that demonstrate the toxicity of the newly formed ADC. In both cases, a “control ADC” with known toxicity against the same target is required to serve as positive control for the assessment of the potency of the new ADC. Via the custom ADC preparation services, Creative Biolabs offers a variety of control ADCs prepared by the conjugation of well-established antibodies and payload-linker complexes. With a large selection of antibodies against numerous cancer targets and scientists with extensive experience in ADC preparation using payload-linker complexes bearing MMAE, DM1, PBD dimer, Duocarmycin, Calicheamicin…, the “control” ADCs from Creative Biolabs are excellent for concept validation and assay development to help with the progression of any R&D projects.
Table 1. List of selected antibodies for control ADC preparation
Antibody
Subclass
Target
Tacatuzumab
IgG1
AFP
Taplitumomab
IgG1
CD19
Denintuzumab
IgG1
CD19
Inotuzumab
IgG4
CD22
Pinatuzumab
IgG1
CD22
Gemtuzumab
IgG4
CD33
Vorsetuzumab
IgG1
CD70
Polatuzumab
IgG1
CD79B
Tucotuzumab
IgG1
EpCAM
Trastuzumab
IgG1
HER2
Capromab
IgG1
FOLH1
Cantuzumab
IgG1
MUC1
Epitumomab
IgG1
MUC1
Lorvotuzumab
IgG1
NCAM1
Indatuximab
IgG4
SDC1
Brentuximab
IgG1
TNFRSF8
Satumomab
IgG1
TAG72
Coltuximab
IgG1
CD19
Gemtuzumab
IgG2
CD33
Lifastuzumab
IgG1
SLC34A2
Sofituzumab
IgG1
MUC16
Bivatuzumab
IgG1
CD44
Denintuzumab
IgG1
CD19
Enfortumab
IgG1
PVRL4
Anetumab
IgG1
MSLN
Table 2. List of selected customized ADC products suitable for control ADC
Product name
Cat. No
Antibody
Target
Anti-AFP (Tacatuzumab)-SMCC-DM1 ADC
ADC-W-656
Tacatuzumab
AFP
Linker-Payload SMCC-DM1
Anti-CD19 (Taplitumomab)-SPDB-DM4 ADC
ADC-W-771
Taplitumomab
CD19
SPDB-DM4
Anti-CD22 (Inotuzumab)-MC-MMAF ADC
ADC-W-2523
Inotuzumab
CD22
MC-MMAF
Anti-CD33 (Gemtuzumab)-MC-Vc-PAB-
ADC-W-2540
Gemtuzumab
CD33
MC-Vc-PAB-
ADC-W-954
Vorsetuzumab
CD70
MC-Vc-PAB-SN38
Anti-CD79B (Polatuzumab)-SMCC-DM1 ADC
ADC-W-2554
Polatuzumab
CD79B
SMCC-DM1
Anti-EPCAM (Tucotuzumab)-SPDB-DM4
ADC-W-1083
Tucotuzumab
EPCAM
SPDB-DM4
Anti-ERBB2 (Trastuzumab)-VC-DUBA ADC ADC-W-514
Trastuzumab
ERBB2
VC-DUBA
Anti-FOLH1 (Capromab)-MC-MMAF ADC
ADC-W-1162
Capromab
FOLH1
MC-MMAF
Anti-MUC1 (Cantuzumab)-MC-Vc-PAB-
ADC-W-1613
Cantuzumab
MUC1
MC-Vc-PAB-
MMAE ADC Anti-CD70 (Vorsetuzumab)-MC-Vc-PAB-
MMAE
SN38 ADC
ADC
MMAE ADC Anti-NCAM1 (Lorvotuzumab )-MC-Vc-PAB-
MMAE ADC-W-2624
Lorvotuzumab
NCAM1
MC-Vc-PAB-SN38
SN38 ADC Anti-SDC1 (Indatuximab)-SMCC-DM1 ADC
ADC-W-2510
Indatuximab
SDC1
SMCC-DM1
Anti-TNFRSF8 (Brentuximab)-SPDB-DM4 ADC
ADC-W-2344
Brentuximab
TNFRSF8
SPDB-DM4
Anti-TAG-72 (Satumomab)-MC-MMAF ADC ADC-W-2158
Satumomab
TAG-72
MC-MMAF
Anti-CD19 (Coltuximab)-MC-Vc-PAB-
ADC-W-2507
Coltuximab
CD19
MC-Vc-PAB-
ADC-W-2541
Gemtuzumab
CD33
MC-Vc-PAB-SN38
Anti-SLC34A2 (Lifastuzumab)-SMCC-DM1 ADC
ADC-W-2571
Lifastuzumab
SLC34A2
SMCC-DM1
Anti-MUC16 (Sofituzumab)-SPDB-DM4 ADC
ADC-W-2566
Sofituzumab
MUC16
SPDB-DM4
MMAE ADC Anti-CD33 (Gemtuzumab)-MC-Vc-PAB-
MMAE
SN38 ADC
Anti-CD44 (Bivatuzumab)-MC-MMAF ADC
ADC-W-2544
Bivatuzumab
CD44
MC-MMAF
Anti-CD19 (Denintuzumab)-MC-Vc-PAB-
ADC-W-2519
Denintuzumab
CD19
MC-Vc-PAB-SN38
Anti-PVRL4 (Enfortumab)-SMCC-DM1 ADC
ADC-W-2396
Enfortumab
PVRL4
SMCC-DM1
Anti-MSLN (Anetumab)-MC-MMAF ADC
ADC-W-2561
Anetumab
MSLN
MC-MMAF
SN38 ADC
The customized ADCs in the list are only a small part of our products, so please visit our website if you want to learn more.
Creative Biolabs offers the most flexible service for control ADC preparation. The control ADCs can be prepared by the conjugation of a selected antibody with an available payload-linker complex to serve as a positive control in proof-of-concept experiments to assess and evaluate the toxicity of the ADCs formulated by a new antibody. Meanwhile, services for the conjugation of a selected antibody with a customized payload-linker complex are also available to help with the validation of the potency of innovative payload-linkers. Control ADCs from Creative Biolabs are also useful in the development of innovative assay methods for ADC characterization. All control ADCs are extensively characterized by method such as SEC, HIC, UV/VIS… to provide a comprehensive profile of the purity, DAR, and payload distribution pattern of the ADC. This basic characterization profile can serve as a baseline for the development of new analytical assay methods or systems for the testing of these parameters of the same ADCs to reflect the improvement and the superiority of the new methods.
Features of the control ADCs from Creative Biolabs • Formulated with well-established antibodies and payload-linkers • Large selection of tumor targets • Full ADC characterization profiles • Positive controls for new ADC development • Suitable for in vitro and in vivo toxicity assay developments • Reagents for new analytical method/system developments
Contact Us USA 45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-357-2254
Fax: 1-631-207-8356
Email:info@creative-biolabs.com
Europe Tel: 44-207-097-1828